NDLI: Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics

Please wait, while we are loading the content...

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application

The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

Erratum to: Immune monitoring technology primer

Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma

Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study

Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade

Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

T cell-NF-κB activation is required for tumor control in vivo

Immune monitoring technology primer: flow and mass cytometry

Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer

Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma

New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

Pembrolizumab

Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

Immune monitoring technology primer

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

Combination immunotherapy: Where do we go from here?

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations

Quantitative real-time PCR assisted cell counting (qPACC) for epigenetic - based immune cell quantification in blood and tissue

29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

JITC launches a new section: commentary and editorials

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

Immune monitoring technology primer: Single Cell Network Profiling (SCNP)

Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients

Immune monitoring technology primer: immunosequencing

nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

Immunotherapeutic approaches to ovarian cancer treatment

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

Year: 2015, Volume: 3, Issue: Suppl 2

Year: 2015, Volume: 3, Issue: Suppl 1

Year: 2014, Volume: 2

Year: 2014, Volume: 1

Year: 2013, Volume: 1

Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics

Content Provider	PubMed Central
Author	Sayour, Elias J. Luis, Sanchez-perez Flores, Catherine Mitchell, Duane A.
Abstract	Tumor-specific immunotherapy holds the promise of eradicating malignant tumors with exquisite precision without additional toxicity to standard treatments. Cancer immunotherapy has conventionally relied on cell-mediated immunity while successful infectious disease vaccines have been shown to induce humoral immunity. Efficacious cancer immunotherapeutics likely require both cellular and humoral responses, and RNA based cancer vaccines are especially suited to stimulate both arms of the immune system. RNA is inherently immunogenic, inducing innate immune responses to initiate cellular and humoral adaptive immunity, but has limited utility based on its poor in vivo stability. Early work utilized ‘naked’ RNA vaccines, whereas more recent efforts have attempted to encapsulate RNA thereby protecting it from degradation. However, feasibility has been limited by a lack of defined and safe targeting mechanisms for the in vivo delivery of stabilized RNA. As new cancer antigens come to the forefront with novel RNA encapsulation and targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to initiate patient-specific anti-tumor efficacy.
Related Links	http://dx.doi.org/10.1186/s40425-015-0058-0
Starting Page	13
File Format	PDF
ISSN	20511426
e-ISSN	20511426
Journal	Journal for Immunotherapy of Cancer
Volume Number	3
Language	English
Publisher	BioMed Central
Publisher Date	2015-12-01
Access Restriction	Open
Rights Holder	BioMed Central
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Cancer Research Pharmacology Immunology Molecular Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics

Repurposing infectious disease vaccines for intratumoral immunotherapy

Human Vaccines and Immunotherapeutics: News. (Journal: Human Vaccines & Immunotherapeutics Volume: 11 Issue: 7)

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy

Reimbursement challenges with cancer immunotherapeutics.

Editorial: Glycoconjugates in vaccines and immunotherapeutics

RNA-Based Vaccines in Cancer Immunotherapy

Antibody targeted CpG for the immunotherapy of solid tumors

Human vaccines & immunotherapeutics: News.

Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics

Similar Documents

Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics

Repurposing infectious disease vaccines for intratumoral immunotherapy

Human Vaccines and Immunotherapeutics: News. (Journal: Human Vaccines & Immunotherapeutics Volume: 11 Issue: 7)

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy

Reimbursement challenges with cancer immunotherapeutics.

Editorial: Glycoconjugates in vaccines and immunotherapeutics

RNA-Based Vaccines in Cancer Immunotherapy

Antibody targeted CpG for the immunotherapy of solid tumors

Human vaccines & immunotherapeutics: News.

Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics